| Literature DB >> 24902030 |
Oussama Mouri1, Gloriat Morizot2, Gert Van der Auwera3, Christophe Ravel4, Marie Passet1, Nathalie Chartrel1, Isabelle Joly1, Marc Thellier5, Stéphane Jauréguiberry6, Eric Caumes6, Dominique Mazier5, Carine Marinach-Patrice7, Pierre Buffet5.
Abstract
BACKGROUND: Cutaneous leishmaniasis is caused by several Leishmania species that are associated with variable outcomes before and after therapy. Optimal treatment decision is based on an accurate identification of the infecting species but current methods to type Leishmania isolates are relatively complex and/or slow. Therefore, the initial treatment decision is generally presumptive, the infecting species being suspected on epidemiological and clinical grounds. A simple method to type cultured isolates would facilitate disease management.Entities:
Mesh:
Year: 2014 PMID: 24902030 PMCID: PMC4046964 DOI: 10.1371/journal.pntd.0002841
Source DB: PubMed Journal: PLoS Negl Trop Dis ISSN: 1935-2727
| Isolate | Patient/disease | MALDI-TOFpeaks | ||||||||||||||||
| # | Source | Identification by reference method | Age/Gender | Country of contamination |
|
|
|
|
|
|
|
|
|
| MALDI-TOF identification using algorithm ( | |||
| 7114 & 11121 | 6153 &7187 | 5987 | 6173 | 6015 | 6234 | 5589 & 11180 | 5630 | 5937 | 5726 w/o 7875 | 5753 | 7875 | 5726 | ||||||
| (±4 & ±7)(3′) | (±3 & ±5) | (±3) | (±3) | (±5) | (±2) | (±3 & ±6) | (±2) | (±2) | (±6 & ±5) | (±3) | (±5) | (±6) | ||||||
| 1 | ITM (5) |
| NA (4) | Bolivia | X | X | X | X | X | X | X |
| ||||||
| 2 | ITM |
| NA | Bolivia | X | X | X | X | X | X | X |
| ||||||
| 3 | ITM |
| NA | Peru | X | X | X | X | X | X |
| |||||||
| 4 | ITM |
| NA | Peru | X | X | X | X | X | X |
| |||||||
| 5 | ITM |
| NA | Peru | X | X | X | X | X | X |
| |||||||
| 6 | Clinical (6) |
| 49/M | Fr. Guy.(7) | X | X | X | X | X | X |
| |||||||
| 7 | Clinical |
| 21/M | Bolivia | X | X | X | X | X | X |
| |||||||
| 8 | Clinical |
| 28/M | Colombia | X | X | X | X | X | X | X |
| ||||||
| 9 | Clinical |
| 49/M | Peru | X | X | X | X | X | X |
| |||||||
| 10 | Clinical |
| 42/M | Brazil | X | X | X | X | X | X |
| |||||||
| 11 | Lab (8) |
| NA | Brazil | X | X | X | X | X | X |
| |||||||
| 12 | Lab |
| NA | NA | X | X | X | X | X | X |
| |||||||
| 13 | Lab |
| NA | NA | X | X | X | X | X | X |
| |||||||
| 14 | Clinical |
| 43/M | Fr. Guy. | X | X | X | X | X | X |
| |||||||
| 15 | Clinical |
| 29/F | NA | X | X | X | X | X |
| ||||||||
| 16 | Lab |
| NA | Costa Rica | X | X | X | X |
| |||||||||
| 17 | ITM |
| NA | Fr. Guy. | X | X | X | X | X | X |
| |||||||
| 18 | ITM |
| NA | Panama | X | X | X | X | X |
| ||||||||
| 19 | ITM |
| NA | Brazil | X | X | X |
| ||||||||||
| 20 | ITM |
| NA | Peru | X | X | X |
| ||||||||||
| 21 | ITM |
| NA | Brazil | X | X | X |
| ||||||||||
| 22 | Lab |
| NA | Morocco | X | X | X | X | X |
| ||||||||
| 23 | Lab |
| NA | Tunisia | X | X | X | X | X |
| ||||||||
| 24 | Clinical |
| 14/F | Mali | X | X | X | X | X |
| ||||||||
| 25 | Clinical |
| 24/M | Mali | X | X | X | X | X |
| ||||||||
| 26 | Clinical |
| 21/F | Mali | X | X | X | X | X |
| ||||||||
| 27 | Lab |
| 62/M | Tunisia | X | X | X | X | X |
| ||||||||
| 28 | Lab |
| NA | NA | X | X | X | X | X |
| ||||||||
| 29 | Lab |
| 72/M | Morocco | X | X | X | X | X |
| ||||||||
| 30 | Clinical |
| 6/F | Tunisia | X | X | X | X | X |
| ||||||||
| 31 | Lab |
| 83/M | Algeria | X | X | X | X | X |
| ||||||||
| 32 | Lab |
| NA | NA | X | X | X | X | X |
| ||||||||
| 33 | Lab |
| NA | NA | X | X | X | X | X |
| ||||||||
| 34 | Clinical |
| 47/F | Tunisia | X | X | X | X | X |
| ||||||||
| 35 | Clinical |
| 9/F | Tunisia | X | X | X | X | X |
| ||||||||
| 36 | Clinical |
| 64/M | Tunisia | X | X | X | X | X |
| ||||||||
| 37 | Lab |
| NA | Tunisia | X | X | X | X | X |
| ||||||||
| 38 | Clinical |
| 12/F | Israel | X | X |
| |||||||||||
| 39 | Lab |
| NA | Syria | X | X | X |
| ||||||||||
| 40 | Clinical |
| 67/M | Turkey | X | X | X |
| ||||||||||
| 41 | Clinical |
| 2/F | Tunisia | X | X | X | X | X | X |
| |||||||
| 42 | IP Paris (11) |
| NA | NA | X | X | X | X |
| |||||||||
| 43 | Clinical |
| 58/F | Turkey | X | X | X | X |
| |||||||||
| 44 | Clinical |
| 61/F | Turkey - China | X | X | X | X |
| |||||||||
| 45 | Lab |
| 54/M | Turkey - Bulgaria. | X | X | X |
| ||||||||||
| 46 | Clinical |
| 29/M | France | X | X | X |
| ||||||||||
(1) L. guy./pan.: L. guyanensis/panamenesis (4) NA: Information not available (8) Lab: Isolate from the laboratory collection, Pitié-Salpêtrière Hospital (2) L. don./inf.: L. donovani/infantum (5) ITM: Tropical Institute, Antwerpen, Belgium (9) L. mex./amazon.: L.mexicana/amazonensis (3) L. don.: L. donovani (6) Clin: Clinical isolate Pitié-Salpêtrière Hospital, Paris, France (10) L. trop./kil: L. tropica/killicki (3′) Observed variation in peak values in Da (7) Fr. Guy.: French Guyana (11) IP Paris: Isolate from the laboratory collection, Insitut Pasteur Medical Center, Paris, France.
Figure 1Cluster analysis of MALDI-TOF MS 184 spectra from 46 Leishmania isolates (A) with distances displayed in relative units [19], and algorithm for a computer-independent interpretation of MALDI-TOF MS (B) based on presence/absence of peaks as displayed on Table 1.
Figure 2Mass spectra from isolates belonging to either L. (V) braziliensis, L. (V) guyanensis ((V) stands for Viannia subgenus), L. (L) major, L. (L) infantum ((L) stands for Leishmania subgenus).
The two pairs of peaks discriminating the Viannia subgenus from the Leishmania subgenus are labeled in green and blue, respectively and indicated by vertical dotted lines. The 11120+/−(7) peak that identifies the Viannia subgenus is shown in insert squares at the right side of the figure to improve readability. Peaks differentiating species complexes are labeled with their corresponding molecular weights in colored squares. The software automatically provides the molecular weights for all peaks above signal background (grey labels). Peaks that identify species in each subgenus are shown in Black. A few peaks above background were not labeled on the figure to improve readability, the complete spectra are provided as supplementary .